Bharat Parenterals Limited has re-appointed Hemang Shah as an Executive Director for a term of five consecutive years, effective from July 02, 2026 to July 01, 2031. The company name Board of Directors approved the decision on August 05, 2026, based on recommendations from the Nomination and Remuneration Committee and the Audit Committee. The appointment remains subject to approval by shareholders at the company’s ensuing Annual General Meeting.

The Board verified that Mr. Shah is not debarred from holding the office of Director by any order of the Ministry of Corporate Affairs (MCA), SEBI, or any other authority. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III and SEBI Master Circular bearing No. HO/49/14/14(7)2025-CFDP2/I/3762/2026 dated January 30, 2026.

Director Profile and Tenure

Hemang Jayendrabhai Shah brings over 30 years of experience to the role and has been associated with Bharat Parenterals Limited for more than two decades. He holds a Bachelor of Commerce degree and a Master of Social Work (MSW). The Board cited his pivotal role in the growth and development of the company as key factors in his re-appointment.

Compliance and Disclosures

The company confirmed that Mr. Shah is not related to any other Director of the company. The detailed disclosures required under the SEBI LODR Regulations have been annexed to the intimation sent to the BSE Limited. The information is also available on the company’s website at www.bplindia.in .

The re-appointment ensures continuity in leadership for the Vadodara-based pharmaceutical manufacturer, which operates under WHO-GMP certification and holds Star Export House status. Shareholders will vote on the resolution during the upcoming Annual General Meeting.

Promoter entity Desai Shares and Stock Private Limited has increased its stake in Bharat Parenterals Limited through an open market acquisition. The entity purchased 1,356 equity shares, raising its total holding to 39.67% of the company's paid-up share capital. The transaction was executed on the BSE and intimated to the company on June 26, 2026.

The acquisition was carried out over a period between June 15, 2026, and June 25, 2026. The total value of the transaction amounted to ₹18.06 lakh. Prior to this purchase, the promoter held 27,32,436 shares, representing a 39.65% stake in the pharmaceutical company.

Details of Acquisition

The disclosure was submitted in accordance with Regulation 29 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The table below outlines the specifics of the shareholding change:

The disclosure was signed by Mr. Bhahim Desai, Director of Desai Shares and Stock Private Limited. Bharat Parenterals Limited's Company Secretary and Compliance Officer, Sharmin Soni, submitted the intimation to the stock exchanges on June 26, 2026.